Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of PTK-7 in Acute Myeloid Leukemias (LAM-PTK7)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02860793
Recruitment Status : Completed
First Posted : August 9, 2016
Last Update Posted : August 10, 2016
Sponsor:
Information provided by (Responsible Party):
Institut Paoli-Calmettes

Brief Summary:

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at:

  • evaluating the impact of PTK7 expression on primary AML cells ex vivo
  • evaluating the diagnostic and prognostic value of a soluble form of PTK7

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Other: Bone marrow aspiration Other: Blood sampling Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Role of PTK-7 in Acute Myeloid Leukemias: Impact of PTK7 Serum Marker and ex Vivo Studies to Decipher the Role of PTK7
Study Start Date : January 2014
Actual Primary Completion Date : April 2015


Arm Intervention/treatment
Experimental: AML patients at diagnosis Other: Bone marrow aspiration
Other: Blood sampling



Primary Outcome Measures :
  1. Evaluation PTK7+ and PTK7- AML cells hematopoietic homing abilities in xenografted mice by in vivo bioluminescence imaging [ Time Frame: 1 day ]
  2. Soluble PTK7 measurement in the serum [ Time Frame: 12 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age> 18 years
  • AML at diagnosis, not previously treated
  • Treatment by induction chemotherapy
  • Signed informed consent
  • Affiliation to the French social security system

Exclusion Criteria:

  • pregnant woman(or of childbearing potential) or breastfeeding woman
  • emergency
  • patients deprived of liberty or placed under the authority of a tutor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02860793


Locations
Layout table for location information
France
Institut Paoli Calmettes
Marseille, Bouches du Rhone, France, 13009
Sponsors and Collaborators
Institut Paoli-Calmettes
Investigators
Layout table for investigator information
Principal Investigator: Norbert VEY, MD Institut Paoli-Calmettes
Layout table for additonal information
Responsible Party: Institut Paoli-Calmettes
ClinicalTrials.gov Identifier: NCT02860793    
Other Study ID Numbers: LAM-PTK7-IPC 2013-011
First Posted: August 9, 2016    Key Record Dates
Last Update Posted: August 10, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Institut Paoli-Calmettes:
PTK7
Acute Myeloid Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms